期刊
FRONTIERS IN ONCOLOGY
卷 11, 期 -, 页码 -出版社
FRONTIERS MEDIA SA
DOI: 10.3389/fonc.2021.634881
关键词
pancreatic ductal adenocarcinoma; SHR-A1403; c-Met antibody-drug conjugate; anti-tumour; cholesterol metabolism
类别
资金
- National Natural Science Foundation of China [81871906, 82073326]
- Shanghai Sailing Program [20YF1426900]
- CSCO2019 Qilu Cancer Research Fund [Y-QL2019-0281]
The new c-MET antibody-drug conjugate SHR-A1403 shows promising potential for targeted treatment of PDAC by significantly inhibiting pancreatic cancer cell proliferation, migration, and invasion, as well as inducing cell cycle arrest and apoptosis through inhibition of intracellular cholesterol biosynthesis. Targeting c-MET through SHR-A1403 demonstrates strong preclinical anti-tumour efficacy in pancreatic cancer.
Pancreatic ductal adenocarcinoma (PDAC) is the fourth leading cause of cancer-associated death in the United States and has a 5-year survival rate of <4%. Although much effort has been invested in the research and development of pancreatic cancer drugs over the past 30 years, due to the lack of effective targetable carcinogenic drivers, no new targeted therapies that can improve patient prognosis have been approved for clinical use. SHR-A1403 is a new c-mesenchymal-epithelial transition factor (c-MET) antibody-drug conjugate that can be used for the targeted treatment of PDAC with high c-MET expression. This study reports for the first time the application prospects of SHR-A1403 in preclinical models of PDAC. SHR-A1403 significantly inhibited the proliferation, migration, and invasion of pancreatic cancer cells and induced cell cycle arrest and apoptosis. These changes were caused by inhibition of intracellular cholesterol biosynthesis by SHR-A1403. Therefore, targeting c-MET through SHR-A1403 showed strong preclinical anti-tumour efficacy in pancreatic cancer. Our work suggests the potential application of c-MET-targeted antibody-drug conjugate treatment for PDAC in clinical practise.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据